Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
Arcturus Therapeutics Holdings Inc. filed a Current Report on Form 8-K dated February 20, 2024, with the report signed on February 23, 2024. The filing concerns a change in the Company’s finance leadership and does not report quarterly or annual financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial performance metrics.
Material Changes
- Keith C. Kummerfeld, Senior Vice President of Finance and Corporate Controller, notified the Company on February 20, 2024 that he would resign effective March 15, 2024 to pursue another opportunity.
- Joseph Roberts, formerly Assistant Controller, was promoted to Controller.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, outlook, management commentary on operations, contingencies, or risk-factor updates. The principal disclosed item is the transition in the Company’s controller function.
Key Facts for Investors to Verify
- Confirm the effective date of Mr. Kummerfeld’s resignation: March 15, 2024.
- Confirm Joseph Roberts’s appointment as Controller and review any subsequent filings for additional details regarding the transition.
- Review the Company’s periodic financial filings for current financial results, liquidity, debt, and operating outlook, which are not included in this Form 8-K.